<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Nutr Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Nutr Sci</journal-id><journal-id journal-id-type="publisher-id">JNS</journal-id><journal-title-group><journal-title>Journal of Nutritional Science</journal-title></journal-title-group><issn pub-type="epub">2048-6790</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25191589</article-id><article-id pub-id-type="pmc">4153334</article-id><article-id pub-id-type="doi">10.1017/jns.2013.35</article-id><article-id pub-id-type="pii">S2048679013000359</article-id><article-id pub-id-type="publisher-id">00035</article-id><article-categories><subj-group subj-group-type="heading"><subject>Nutritional Immunology</subject></subj-group></article-categories><title-group><article-title>Oral intake of heat-killed <italic>Lactobacillus plantarum</italic> L-137
decreases the incidence of upper respiratory tract infection in healthy subjects with high
levels of psychological stress</article-title><alt-title alt-title-type="left-running">Yoshitaka Hirose <italic>et al</italic></alt-title><alt-title alt-title-type="right-running">Oral intake of heat-killed <italic>Lactobacillus
plantarum</italic> L-137 decreases the incidence of upper respiratory tract infection in
healthy subjects with high levels of psychological stress</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hirose</surname><given-names>Yoshitaka</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Yamamoto</surname><given-names>Yoshihiro</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yoshikai</surname><given-names>Yasunobu</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Murosaki</surname><given-names>Shinji</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Research and Development Institute, House Wellness
Foods Corp.</institution>, <addr-line>Itami</addr-line>, <country>Japan</country></aff><aff id="aff2"><label>2</label><addr-line>Research Center for Infectious Diseases</addr-line>,
<institution>Medical Institute of Bioregulation, Kyushu University</institution>,
<addr-line>Kyushu</addr-line>, <country>Japan</country></aff><author-notes><corresp id="cor1"><label>*</label><addr-line><bold>Corresponding author:</bold> Dr Y.
Hirose</addr-line>, fax <fax>+81 72 778 0892</fax>, email <email>Hirose_Yoshitaka@house-wf.co.jp</email></corresp></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>6</day><month>12</month><year>2013</year></pub-date><volume>2</volume><elocation-id>e39</elocation-id><history><date date-type="received"><day>17</day><month>6</month><year>2013</year></date><date date-type="rev-recd"><day>06</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>16</day><month>10</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2013</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access"><license-p><!--CREATIVE COMMONS-->The online version of this article is published within an Open Access
environment subject to the conditions of the Creative Commons Attribution license
&#x0003c;<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="S2048679013000359a.pdf"/><abstract abstract-type="normal"><p>The immunomodulatory effects of live or non-viable lactic acid bacteria have been
extensively investigated. We reported that oral intake of heat-killed
<italic>Lactobacillus plantarum</italic> L-137 (HK L-137) augmented innate and acquired
immunity in mice and human subjects. To examine the effects of HK L-137 intake on upper
respiratory tract infection (URTI) symptoms and immune functions in human subjects, a
randomised, double-blind, placebo-controlled, parallel study was conducted in subjects
with high psychological stress levels. A total of seventy-eight healthy subjects
(thirty-three men and forty-five women; mean age 50&#x000b7;6 years) with scores of&#x000a0;&#x0003e;41 on
eighteen-item subscales of psychological distress in the Brief Job Stress Questionnaire
were randomly assigned to receive a tablet containing HK L-137 (10&#x000a0;mg) or a placebo tablet
daily for 12 weeks. The URTI symptoms were rated once daily on the validated
twenty-one-item Wisconsin Upper Respiratory Symptom Survey-21. Immune functions, such as
concanavalin A-induced proliferation and percentages of interferon (IFN)-&#x003b3;- and
IL-4-producing CD4 T cells of peripheral blood mononuclear cells (PBMC), and serum IFN-&#x003b2;
concentrations were measured every 4 weeks. URTI incidence was significantly lower in the
HK L-137 group than in the control group. URTI incidence, duration and severity, and
duration of medication showed significant negative correlations with duration of HK L-137
intake. The percentage change from baseline of concanavalin A-induced proliferation of
PBMC was significantly greater in the HK L-137 group than in the control group. These
findings suggest that daily HK L-137 intake can decrease URTI incidence in healthy
subjects, possibly through augmentation of immune functions.</p></abstract><kwd-group><title>Key words</title><kwd><italic>Lactobacillus plantarum</italic></kwd><kwd>Immune function</kwd><kwd>Wisconsin Upper Respiratory Symptom Survey</kwd><kwd>Upper respiratory tract infections</kwd><kwd>Stress</kwd></kwd-group><kwd-group kwd-group-type="abbreviations"><title>Abbreviations</title><kwd>Con A, concanavalin A</kwd><kwd>HK L-137, heat-killed <italic>Lactobacillus plantarum</italic> L-137</kwd><kwd>IFN, interferon</kwd><kwd>PBMC, peripheral blood mononuclear cells</kwd><kwd>Th, T helper</kwd><kwd>URTI, upper respiratory tract infection</kwd><kwd>WURSS, Wisconsin Upper Respiratory Symptom Survey</kwd><kwd>WURSS-21, short-form Wisconsin Upper Respiratory Symptom Survey</kwd><kwd>WURSS-44, long-form Wisconsin Upper Respiratory Symptom Survey</kwd></kwd-group><counts><fig-count count="1"/><table-count count="3"/><ref-count count="51"/><page-count count="8"/></counts></article-meta></front><body><p>Lactobacilli, non-pathogenic Gram-positive inhabitants of the normal human intestine, are
known as probiotics for their health-promoting effects, including enhancement of the immune
system, protection against intestinal infection, reduction of serum cholesterol
concentrations, and anticarcinogenic activities<sup>(</sup><xref rid="ref1" ref-type="bibr">
<sup>1</sup>
</xref><sup>)</sup>. Although probiotics were originally defined as live microbial food
components, non-viable microbes have also been shown to exhibit beneficial effects that are
equivalent to, or even greater than, those of live microbes<sup>(</sup><xref rid="ref2" ref-type="bibr">
<sup>2</sup>
</xref><sup>,</sup><xref rid="ref3" ref-type="bibr">
<sup>3</sup>
</xref><sup>)</sup>. Recently, bacteria that promote health by driving mucosal immune
mechanisms have been defined as immunobiotics<sup>(</sup><xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref><sup>)</sup>.</p><p>Heat-killed <italic>Lactobacillus plantarum</italic> L-137 (HK L-137), a strain isolated from
fermented food, is a potent inducer of IL-12, which leads to a T helper (Th) 1-type immune
response and subsequent anti-allergic or anti-tumour effects in mouse models<sup>(</sup><xref rid="ref5" ref-type="bibr">
<sup>5</sup>
</xref><sup>&#x02013;</sup><xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref><sup>)</sup>. We have illustrated previously that heat treatment of L-137 hardly
changes bacterial cell size but enhances immunomodulatory activity and stability in simulated
digestive juices<sup>(</sup><xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref><sup>)</sup>. Moreover, it was also reported that daily intake of HK L-137 enhances
Th1-related immune functions, such as increased concanavalin A (Con A)-induced proliferation
and percentages of interferon (IFN)-&#x003b3;- and IL-4-producing CD4 T cells (Th1:Th2 ratio) of
peripheral blood mononuclear cells (PBMC) in healthy subjects<sup>(</sup><xref rid="ref9" ref-type="bibr">
<sup>9</sup>
</xref><sup>)</sup>. In a recent study, we demonstrated that oral administration of HK L-137
enhances protection against influenza virus infection by stimulation of type I IFN production
in mice<sup>(</sup><xref rid="ref10" ref-type="bibr">
<sup>10</sup>
</xref><sup>)</sup>. Furthermore, we observed increased production of type I IFN after intake
of HK L-137 in human subjects<sup>(</sup><xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref><sup>)</sup>. These findings suggest that HK L-137 may boost host defence against
common cold infections, including influenza A virus infection, in humans.</p><p>Physical and psychological stress is one of the factors that lowers immune functions,
together with malnutrition, ageing, intense exercise and undesirable
lifestyles<sup>(</sup><xref rid="ref12" ref-type="bibr">
<sup>12</sup>
</xref><sup>)</sup>. It is now well established that the immune, endocrine and central nervous
systems interact, and that psychological stress causes dysregulation of immune responses via
effects on the hypothalamic&#x02013;pituitary&#x02013;adrenal axis and the autonomic nervous
system<sup>(</sup><xref rid="ref13" ref-type="bibr">
<sup>13</sup>
</xref><sup>)</sup>. Many studies have indicated that psychological stress score is strongly
correlated with an increased risk of not only acute infectious respiratory illness, but also
development of acute and chronic fatigue syndromes<sup>(</sup><xref rid="ref14" ref-type="bibr">
<sup>14</sup>
</xref><sup>&#x02013;</sup><xref rid="ref17" ref-type="bibr">
<sup>17</sup>
</xref><sup>)</sup>. These observations suggest that individuals under high levels of
psychological stress are susceptible to catching a cold.</p><p>The common cold is a clinical syndrome resulting from viral infection of the upper
respiratory tract. Although upper respiratory tract infection (URTI) is extremely common,
accounting for up to half of all acute illness episodes<sup>(</sup><xref rid="ref18" ref-type="bibr">
<sup>18</sup>
</xref><sup>)</sup>, there are no perfect tools for assessing common cold infections,
including URTI. The Wisconsin Upper Respiratory Symptom Survey (WURSS) was developed using
individual interviews and focus groups among community-recruited individuals with
Jackson-defined colds<sup>(</sup><xref rid="ref19" ref-type="bibr">
<sup>19</sup>
</xref><sup>)</sup>. The semi-structured interviews included open-ended questions aimed at
eliciting terminology and assessing health values related to experience of a cold-related
illness. Of more than 150 terms used to define symptomatic or functional impairment,
forty-four were chosen for inclusion in the long-form WURSS-44<sup>(</sup><xref rid="ref19" ref-type="bibr">
<sup>19</sup>
</xref><sup>)</sup> and twenty-one were selected for inclusion in a shorter form, the
WURSS-21<sup>(</sup><xref rid="ref20" ref-type="bibr">
<sup>20</sup>
</xref><sup>)</sup>. The WURSS-44 and WURSS-21 have been widely validated and confirmed to
perform well as illness-specific quality-of-life evaluative outcome instruments. Therefore,
these self-rating questionnaires may be good tools for assessing the symptoms of URTI.</p><p>The objective of the present study was to examine the effects of HK L-137 intake on the
incidence and severity of URTI using the WURSS-21 in healthy subjects with high levels of
psychological stress, in addition to its effects on immune functions.</p><sec id="sec1"><title>Experimental methods</title><sec id="sec1-1" sec-type="subjects"><title>Subjects</title><p>Healthy subjects under stress aged 40&#x02013;64 years were recruited from October 2011 to
December 2011 and were assessed for eligibility to take part in the present study. Stress
response in the subjects was examined by the Japan Brief Job Stress
Questionnaire<sup>(</sup><xref rid="ref21" ref-type="bibr">
<sup>21</sup>
</xref><sup>)</sup>. The questionnaire was developed by a stress assessment study group,
&#x02018;The Study Group for the Prevention of Work-Related Disease&#x02019;, of the Japanese Ministry of
Health, Labour and Welfare (1995&#x02013;1998). It is used to assess total job stress with
subscales of: (a) job stressor; (b) job stress response; (c) social support; and (d)
degree of satisfaction. The job stress response includes six psychological (eighteen items
on vigor, impatience, fatigue, anxiety and depression) stress response subscales, which
were used in the present study. The subjects rated their response to each question from 1
(not at all) to 4 (yes, absolutely), and their psychological distress was estimated from
the total score of the sum of the eighteen items (score range 18&#x02013;72). It was reported that
the total scores can be classified into five groups based on the evaluation of 11847
subjects: highest (51&#x02013;72; 8&#x000b7;4 %); second highest (42&#x02013;50; 19&#x000b7;4 %); moderate (33&#x02013;41; 37&#x000b7;7
%); second lowest (24&#x02013;32; 30&#x000b7;2 %); and lowest (18&#x02013;23; 4&#x000b7;3 %)<sup>(</sup><xref rid="ref21" ref-type="bibr">
<sup>21</sup>
</xref><sup>)</sup>. In accordance with this classification, subjects with total scores
of&#x000a0;&#x0003e;41 were defined as having high levels of psychological stress in the present
study. The inclusion criterion was being a healthy subject with a score of&#x000a0;&#x0003e;41 for
the eighteen-item subscales of psychological distress in the Japan Brief Job Stress
Questionnaire. Exclusion criteria included current history of illness including diabetes,
liver disease, renal disease, cardiac disease, and inappropriate secretion of adrenal
cortex hormone, or a previous history of these diseases, allergic disease or intolerance
of milk, current treatment with a prescribed medicine, poor compliance with the clinical
trial guidelines, and being an inappropriate subject as judged by the investigator. Among
126 healthy subjects recruited, seventy-eight subjects (thirty-three men and forty-five
women; mean age 50&#x000b7;6 years) were eligible and randomly assigned (<xref ref-type="fig" rid="fig01">Fig. 1</xref>). Sample size was determined based on previous studies of the
effects of probiotics on URTI<sup>(</sup><xref rid="ref22" ref-type="bibr">
<sup>22</sup>
</xref><sup>,</sup><xref rid="ref23" ref-type="bibr">
<sup>23</sup>
</xref><sup>)</sup>. A sample size estimation of sixty-four subjects was based on an
expected rate of 2&#x000b7;0 (<sc>sd</sc> 1&#x000b7;0) URTI episodes during the winter
months<sup>(</sup><xref rid="ref24" ref-type="bibr">
<sup>24</sup>
</xref><sup>)</sup>, a target 25 % reduction in the number of episodes, statistical power
of 80 %, and a type I error of 5 %. We initially recruited seventy-eight volunteers to
account for an estimated 20 % drop-out rate over the study period. Eating habits were not
considered for the criteria, but the subjects were instructed to continue their habitual
diets during the study. Approval of the protocol was obtained from the Nihonbashi
Cardiology Clinic Ethical Review Board (Tokyo, Japan), and the study was conducted in
accordance with the Declaration of Helsinki of 1975 as revised in 2008 and with the
ethical guidelines for epidemiological research proposed by the Ministry of Education,
Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare.
The procedures were fully explained to the subjects, and written informed consent was
obtained from each subject before the beginning of the study. <fig id="fig01" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Subject flowchart summarised according to Consolidated Standards of Reporting
Trials (CONSORT) that shows the number of subjects randomly assigned, lost to
follow-up and analysed by treatment arm. HK L-137, heat-killed <italic>Lactobacillus
plantarum</italic> L-137; URTI, upper respiratory tract infection.</p></caption><graphic xlink:href="S2048679013000359_fig1"/></fig></p></sec><sec id="sec1-2"><title>Preparation of heat-killed <italic>Lactobacillus plantarum</italic> L-137</title><p>LP20 (House Wellness Foods Corporation), which contains 20 % HK L-137 and 80 % dextrin,
was used in the present study. The preparation of HK L-137 for LP20 was carried out on the
basis of a previously described method<sup>(</sup><xref rid="ref5" ref-type="bibr">
<sup>5</sup>
</xref><sup>)</sup>.</p></sec><sec id="sec1-3"><title>Experimental design</title><p>A total of seventy-eight healthy subjects were enrolled in a randomised, double-blind,
placebo-controlled, parallel study. The subjects were randomly assigned to two groups
using a sequential series of numbered sealed envelopes that each contained one food
ingredient assigned in a computer-randomised manner. After the assignment, the subjects
consumed either a tablet containing 50&#x000a0;mg of LP20 (one tablet daily) or a matching control
tablet, in which LP20 was substituted with dextrin, for 12 weeks. Throughout the study,
the subjects rated themselves once daily in a subject diary to assess their general
health, duration of medication, and compliance with the dietary regimens, and by the
self-rating questionnaire to examine URTI symptoms. Blood samples were collected every 4
weeks, and biomarkers for immune function were also measured every 4 weeks. Safety
assessments, such as anthropometric measurements, biochemical examinations of blood,
haematological assessments and urine tests, were performed at 0 and 12 weeks. Measurements
of the biomarkers and blood and urine tests were completed by a clinical laboratory
testing company, SRL. The study was conducted at Nihonbashi Cardiology Clinic (Tokyo,
Japan) from December 2011 to March 2012.</p></sec><sec id="sec1-4"><title>Upper respiratory tract infection symptoms</title><p>The incidence and severity of URTI symptoms were rated once daily on the WURSS-21
described in online Supplementary Appendix S1<sup>(</sup><xref rid="ref19" ref-type="bibr">
<sup>19</sup>
</xref><sup>,</sup><xref rid="ref20" ref-type="bibr">
<sup>20</sup>
</xref><sup>)</sup>, Japanese version. The first item, which reflected mental severity,
was assessed separately. The subsequent nineteen items, which included ten items of cold
symptoms and nine items of quality-of-life functional impairment, were used to evaluate
the physical severity of URTI. The subjects answered the first item every day by marking a
0&#x02013;7 Likert-type severity scale, where 0&#x000a0;=&#x000a0;not sick, 1&#x000a0;=&#x000a0;very mildly, 3&#x000a0;=&#x000a0;mildly,
5&#x000a0;=&#x000a0;moderately, and 7&#x000a0;=&#x000a0;severely. The date of onset of cold illness was defined as the day
of marking a number other than 0 after two previous markings of 0. If the subjects marked
numbers other than 0 on the first or second day after the beginning of dietary
intervention, the day was included as the date of onset. The scores for the incidence and
duration of URTI were defined as the number of new onsets and the sum of days of marking
numbers other than 0, respectively. The subjects who marked numbers other than 0 answered
the following nineteen items by rating on a conventional Likert scale for cold symptoms,
in which 0&#x000a0;=&#x000a0;do not have this symptom, 1&#x000a0;=&#x000a0;very mild, 3&#x000a0;=&#x000a0;mild, 5&#x000a0;=&#x000a0;moderate, and
7&#x000a0;=&#x000a0;severe, and quality of life, in which 0&#x000a0;=&#x000a0;not at all, 1&#x000a0;=&#x000a0;very mildly, 3&#x000a0;=&#x000a0;mildly,
5&#x000a0;=&#x000a0;moderately, and 7&#x000a0;=&#x000a0;severely. The scores of mental severity and physical severity were
defined as the sums of the scales of the first item and of the following nineteen items,
respectively.</p></sec><sec id="sec1-5"><title>Medication</title><p>When the subjects used drugs during the study, they recorded the names of the drugs in
the subject diary. If an anti-inflammatory drug was used on the day of marking a number
other than zero in the first item, the drug use was defined as medication.</p></sec><sec id="sec1-6"><title>Biomarkers for immune functions</title><p>PBMC were isolated by the Ficoll&#x02013;Conray centrifugation technique (Ficoll&#x02013;Conray,
<italic>d</italic>&#x000a0;=&#x000a0;1&#x000b7;077). PBMC (5&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells/ml) were cultured with or
without the optimal dose of Con A (5 &#x000b5;g/ml) for 72&#x000a0;h at 37&#x000b0;C, and pulse labelled with 37
kBq of [<sup>3</sup>H]thymidine during the last 8&#x000a0;h. DNA synthesis was assessed by
measuring thymidine uptake. The percentages of IFN-&#x003b3;- and IL-4-producing CD4<sup>+</sup> T
cells (Th1:Th2 ratio) were determined by single-cell measurements of intracellular
cytokines using flow cytometry, as described<sup>(</sup><xref rid="ref25" ref-type="bibr">
<sup>25</sup>
</xref><sup>)</sup>. Serum IFN-&#x003b2; concentrations were determined using an ELISA kit (PBL
Biomedical Laboratories) according to the manufacturer's instructions.</p></sec><sec id="sec1-7"><title>Statistical analysis</title><p>We compared the baseline values between the two groups using the unpaired
<italic>t</italic> test for age, Con A-induced proliferation and Th1:Th2 ratio, and the
Mann&#x02013;Whitney <italic>U</italic> test for total psychological stress score. Because most
serum IFN-&#x003b2; concentrations in subjects were below the detection limit, the difference in
baseline concentrations in serum IFN-&#x003b2; between the two groups was also assessed by the
Mann&#x02013;Whitney <italic>U</italic> test. The scores for the incidence, duration, mental
severity and physical severity of URTI, and duration of medication in each group were
calculated every week and analysed by the Friedman test<sup>(</sup><xref rid="ref26" ref-type="bibr">
<sup>26</sup>
</xref><sup>,</sup><xref rid="ref27" ref-type="bibr">
<sup>27</sup>
</xref><sup>)</sup>. The correlations between the incidence, duration, mental severity and
physical severity of URTI, and duration of medication and the duration of HK L-137 intake
were analysed using Spearman's rank-correlation coefficient test. The percentage changes
from baseline in the measurements of immune functions other than serum IFN-&#x003b2; concentration
were analysed by two-way ANOVA, followed by comparisons between the two groups at each
time point using the unpaired <italic>t</italic> test. The changes from baseline in the
serum IFN-&#x003b2; concentrations between the two groups were assessed by the Mann&#x02013;Whitney
<italic>U</italic> test. All analyses were performed using PASW version 18.0J (SPSS
Japan). A probability value of <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;05 was considered to indicate
statistical significance.</p></sec></sec><sec sec-type="results" id="sec2"><title>Results</title><sec id="sec2-1"><title>Baseline characteristics</title><p>All of the seventy-eight subjects completed the study and were included in the
statistical analyses of the URTI symptoms. The baseline immune characteristics and
psychological stress scores are shown in <xref ref-type="table" rid="tab01">Table
1</xref>. None of the characteristics showed any differences between the two groups.
<table-wrap id="tab01" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline psychological stress scores and immune characteristics of the subjects
enrolled in the present study</p><p>(Mean values and standard deviations)</p></caption><alternatives><graphic xlink:href="S2048679013000359_tab1"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Control</th><th align="center" colspan="2" rowspan="1">HK L-137</th><th align="center" colspan="2" rowspan="1">All subjects</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Subjects (<italic>n</italic>)</td><td align="center" colspan="2" rowspan="1">39</td><td align="center" colspan="2" rowspan="1">39</td><td align="center" colspan="2" rowspan="1">78</td></tr><tr><td rowspan="1" colspan="1">Sex (<italic>n</italic>)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x000a0;Male</td><td align="center" colspan="2" rowspan="1">14</td><td align="center" colspan="2" rowspan="1">19</td><td align="center" colspan="2" rowspan="1">33</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Female</td><td align="center" colspan="2" rowspan="1">25</td><td align="center" colspan="2" rowspan="1">20</td><td align="center" colspan="2" rowspan="1">45</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">51&#x000b7;5</td><td rowspan="1" colspan="1">7&#x000b7;2</td><td rowspan="1" colspan="1">49&#x000b7;6</td><td rowspan="1" colspan="1">6&#x000b7;8</td><td rowspan="1" colspan="1">50&#x000b7;6</td><td rowspan="1" colspan="1">7&#x000b7;0</td></tr><tr><td rowspan="1" colspan="1">Immune function</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x000a0;Unstimulated proliferation (&#x000d7;10<sup>3</sup> cpm)</td><td rowspan="1" colspan="1">0&#x000b7;23</td><td rowspan="1" colspan="1">0&#x000b7;12</td><td rowspan="1" colspan="1">0&#x000b7;22</td><td rowspan="1" colspan="1">0&#x000b7;09</td><td rowspan="1" colspan="1">0&#x000b7;23</td><td rowspan="1" colspan="1">0&#x000b7;11</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Con A-induced proliferation (&#x000d7;10<sup>3</sup> cpm)</td><td rowspan="1" colspan="1">29&#x000b7;3</td><td rowspan="1" colspan="1">6&#x000b7;9</td><td rowspan="1" colspan="1">28&#x000b7;4</td><td rowspan="1" colspan="1">9&#x000b7;0</td><td rowspan="1" colspan="1">28&#x000b7;8</td><td rowspan="1" colspan="1">8&#x000b7;0</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;IFN-&#x003b3;-producing cells (Th1 cells) (%
CD4<sup>+</sup> cells)</td><td rowspan="1" colspan="1">22&#x000b7;6</td><td rowspan="1" colspan="1">8&#x000b7;1</td><td rowspan="1" colspan="1">23&#x000b7;4</td><td rowspan="1" colspan="1">7&#x000b7;0</td><td rowspan="1" colspan="1">23&#x000b7;0</td><td rowspan="1" colspan="1">7&#x000b7;5</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;IL-4-producing cells (Th2 cells) (% CD4<sup>+</sup>
cells)</td><td rowspan="1" colspan="1">2&#x000b7;9</td><td rowspan="1" colspan="1">1&#x000b7;2</td><td rowspan="1" colspan="1">2&#x000b7;6</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">2&#x000b7;7</td><td rowspan="1" colspan="1">1&#x000b7;1</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Th1:Th2 ratio</td><td rowspan="1" colspan="1">9&#x000b7;2</td><td rowspan="1" colspan="1">5&#x000b7;2</td><td rowspan="1" colspan="1">10&#x000b7;4</td><td rowspan="1" colspan="1">5&#x000b7;2</td><td rowspan="1" colspan="1">9&#x000b7;8</td><td rowspan="1" colspan="1">5&#x000b7;2</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Serum IFN-&#x003b2; (IU/ml)*</td><td rowspan="1" colspan="1">11&#x000b7;3</td><td rowspan="1" colspan="1">35&#x000b7;1</td><td rowspan="1" colspan="1">17&#x000b7;4</td><td rowspan="1" colspan="1">49&#x000b7;3</td><td rowspan="1" colspan="1">14&#x000b7;3</td><td rowspan="1" colspan="1">42&#x000b7;6</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Total psychological stress scores*</td><td rowspan="1" colspan="1">59&#x000b7;6</td><td rowspan="1" colspan="1">4&#x000b7;4</td><td rowspan="1" colspan="1">58&#x000b7;5</td><td rowspan="1" colspan="1">4&#x000b7;0</td><td rowspan="1" colspan="1">59&#x000b7;0</td><td rowspan="1" colspan="1">4&#x000b7;2</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>HK L-137, heat-killed <italic>Lactobacillus plantarum</italic> L-137; Con A,
concanavalin A; cpm, counts per min; IFN, interferon; Th1, type 1 T helper; Th2,
type 2 T helper.</p></fn><fn><p>* Compared between the two groups by the Mann&#x02013;Whitney <italic>U</italic>
test.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2-2"><title>Effects of dietary intervention on upper respiratory tract infection symptoms</title><p>During the study, twenty-four subjects in the control group contracted URTI with a total
of forty-seven times, and nineteen subjects in the HK L-137 group contracted URTI with a
total of thirty-five times. The incidence of URTI during the study was significantly lower
in the HK L-137 group than in the control group (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;011), while no
differences in the other endpoints were observed between the two groups (<xref ref-type="table" rid="tab02">Table 2</xref>). The incidence
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;029), duration (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;005), mental severity
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;005) and physical severity (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;007) of URTI,
and duration of medication (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;008) showed significant negative
correlations with duration of HK L-137 intake (<xref ref-type="table" rid="tab02">Table
2</xref>). <table-wrap id="tab02" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Scores for incidence, duration, mental severity and physical severity of upper
respiratory tract infection (URTI), and duration of medication in subjects with
daily intake of a tablet containing 10&#x000a0;mg of heat-killed <italic>Lactobacillus
plantaru m</italic> L-137 (HK L-137) or a control tablet<xref ref-type="table-fn" rid="tfn2_1">*</xref></p></caption><alternatives><graphic xlink:href="S2048679013000359_tab2"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" colspan="12" rowspan="1">Intervention period</th><th align="center" colspan="2" rowspan="1">Friedman test: <italic>P</italic>&#x02020;</th><th align="center" colspan="2" rowspan="1">Spearman's rank-correlation
coefficient&#x02021;</th></tr><tr><th align="left" rowspan="1" colspan="1">End point</th><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">1 week</th><th align="center" rowspan="1" colspan="1">2 weeks</th><th align="center" rowspan="1" colspan="1">3 weeks</th><th align="center" rowspan="1" colspan="1">4 weeks</th><th align="center" rowspan="1" colspan="1">5 weeks</th><th align="center" rowspan="1" colspan="1">6 weeks</th><th align="center" rowspan="1" colspan="1">7 weeks</th><th align="center" rowspan="1" colspan="1">8 weeks</th><th align="center" rowspan="1" colspan="1">9 weeks</th><th align="center" rowspan="1" colspan="1">10 weeks</th><th align="center" rowspan="1" colspan="1">11 weeks</th><th align="center" rowspan="1" colspan="1">12 weeks</th><th align="center" rowspan="1" colspan="1">Intervention</th><th align="center" rowspan="1" colspan="1">Time point</th><th align="center" rowspan="1" colspan="1">Correlation coefficient</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Incidence (number of cases)</td><td align="left" rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0&#x000b7;011</td><td rowspan="1" colspan="1">0&#x000b7;075</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;619</td><td rowspan="1" colspan="1">0&#x000b7;032</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HK L-137</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0&#x000b7;627</td><td rowspan="1" colspan="1">0&#x000b7;029</td></tr><tr><td rowspan="1" colspan="1">Duration (d)</td><td align="left" rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">1&#x000b7;000</td><td rowspan="1" colspan="1">0&#x000b7;172</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;165</td><td rowspan="1" colspan="1">0&#x000b7;609</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">HK L-137</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0&#x000b7;753</td><td rowspan="1" colspan="1">0&#x000b7;005</td></tr><tr><td rowspan="1" colspan="1">Mental severity</td><td align="left" rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">0&#x000b7;564</td><td rowspan="1" colspan="1">0&#x000b7;445</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;098</td><td rowspan="1" colspan="1">0&#x000b7;761</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">HK L-137</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">73</td><td rowspan="1" colspan="1">58</td><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0&#x000b7;776</td><td rowspan="1" colspan="1">0&#x000b7;005</td></tr><tr><td rowspan="1" colspan="1">Physical severity</td><td align="left" rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">280</td><td rowspan="1" colspan="1">271</td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">205</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">296</td><td rowspan="1" colspan="1">54</td><td rowspan="1" colspan="1">171</td><td rowspan="1" colspan="1">115</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">249</td><td rowspan="1" colspan="1">137</td><td rowspan="1" colspan="1">0&#x000b7;564</td><td rowspan="1" colspan="1">0&#x000b7;443</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;224</td><td rowspan="1" colspan="1">0&#x000b7;484</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">HK L-137</td><td rowspan="1" colspan="1">209</td><td rowspan="1" colspan="1">953</td><td rowspan="1" colspan="1">883</td><td rowspan="1" colspan="1">492</td><td rowspan="1" colspan="1">202</td><td rowspan="1" colspan="1">137</td><td rowspan="1" colspan="1">226</td><td rowspan="1" colspan="1">273</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">169</td><td rowspan="1" colspan="1">104</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0&#x000b7;734</td><td rowspan="1" colspan="1">0&#x000b7;007</td></tr><tr><td rowspan="1" colspan="1">Duration of medication (d)</td><td align="left" rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">0&#x000b7;132</td><td rowspan="1" colspan="1">0&#x000b7;548</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;117</td><td rowspan="1" colspan="1">0&#x000b7;718</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">HK L-137</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0&#x000b7;722</td><td rowspan="1" colspan="1">0&#x000b7;008</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tfn2_1"><label>*</label><p>Control group, <italic>n</italic> 39; HK L-137 group, <italic>n</italic> 39.</p></fn><fn><p>&#x02020; Significant differences estimated between the two groups at the time
points.</p></fn><fn><p>&#x02021; Correlations between the symptoms of URTI, and duration of medication and
duration of control tablet or HK L-137 intake.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2-3"><title>Effects of dietary intervention on immune functions</title><p>The subjects who contracted URTI during the intervention were excluded from the analyses
of immune functions, because the symptoms of URTI can considerably affect immunity. As a
result, a total of thirty-five subjects were included in the statistical analyses of
immune functions (<xref ref-type="fig" rid="fig01">Fig. 1</xref>). The percentage change
in Con A-induced proliferation was significantly higher in the HK L-137 group than in the
control group during the study (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;048), whereas no difference was
observed in the percentage change of unstimulated proliferation between the two groups
(<xref ref-type="table" rid="tab03">Table 3</xref>). The percentage changes in the
Th1:Th2 ratios and the amounts of change in the serum IFN-&#x003b2; concentrations showed no
differences between the two groups (<xref ref-type="table" rid="tab03">Table 3</xref>).
<table-wrap id="tab03" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Percentage changes in immune characteristics from baseline in subjects with daily
intake of a tablet containing 10&#x000a0;mg of heat-killed <italic>Lactobacillus
plantarum</italic> L-137 (HK L-137) or a control tablet without upper respiratory
tract infection (URTI) symptoms throughout the intervention period*</p><p>(Mean values and standard deviations)</p></caption><alternatives><graphic xlink:href="S2048679013000359_tab3"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" colspan="6" rowspan="1">Change from baseline (%)</th><th align="center" colspan="3" rowspan="1">ANOVA: <italic>P</italic>&#x02020;</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">4 weeks</th><th align="center" colspan="2" rowspan="1">8 weeks</th><th align="center" colspan="2" rowspan="1">12 weeks</th><th align="center" rowspan="1" colspan="1">Intervention</th><th align="center" rowspan="1" colspan="1">Time point</th><th align="center" rowspan="1" colspan="1">Interaction&#x02021;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Unstimulated proliferation (&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup> cpm)</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">22&#x000b7;5</td><td rowspan="1" colspan="1">73&#x000b7;7</td><td rowspan="1" colspan="1">8&#x000b7;1</td><td rowspan="1" colspan="1">37&#x000b7;9</td><td rowspan="1" colspan="1">&#x02013;0&#x000b7;5</td><td rowspan="1" colspan="1">38&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;425</td><td rowspan="1" colspan="1">0&#x000b7;016</td><td rowspan="1" colspan="1">0&#x000b7;566</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HK L-137</td><td rowspan="1" colspan="1">29&#x000b7;9</td><td rowspan="1" colspan="1">90&#x000b7;1</td><td rowspan="1" colspan="1">&#x02013;5&#x000b7;3</td><td rowspan="1" colspan="1">34&#x000b7;9</td><td rowspan="1" colspan="1">&#x02013;21&#x000b7;4</td><td rowspan="1" colspan="1">37&#x000b7;1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Con A-induced proliferation (&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup> cpm)</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">&#x02212;22&#x000b7;4</td><td rowspan="1" colspan="1">18&#x000b7;1</td><td rowspan="1" colspan="1">&#x02013;13&#x000b7;1</td><td rowspan="1" colspan="1">22&#x000b7;0</td><td rowspan="1" colspan="1">&#x02212;7&#x000b7;8</td><td rowspan="1" colspan="1">28&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;048</td><td rowspan="1" colspan="1">0&#x000b7;535</td><td rowspan="1" colspan="1">0&#x000b7;679</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HK L-137</td><td rowspan="1" colspan="1">&#x02212;3&#x000b7;8</td><td rowspan="1" colspan="1">28&#x000b7;9</td><td rowspan="1" colspan="1">&#x02013;3&#x000b7;9</td><td rowspan="1" colspan="1">37&#x000b7;4</td><td rowspan="1" colspan="1">&#x02013;0&#x000b7;9</td><td rowspan="1" colspan="1">32&#x000b7;4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">IFN-&#x003b3;-producing cells (Th1 cells) (%CD4<sup>+</sup>
cells)</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">9&#x000b7;1</td><td rowspan="1" colspan="1">18&#x000b7;1</td><td rowspan="1" colspan="1">1&#x000b7;6</td><td rowspan="1" colspan="1">12&#x000b7;6</td><td rowspan="1" colspan="1">8&#x000b7;5</td><td rowspan="1" colspan="1">17&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;455</td><td rowspan="1" colspan="1">0&#x000b7;360</td><td rowspan="1" colspan="1">0&#x000b7;883</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HK L-137</td><td rowspan="1" colspan="1">5&#x000b7;8</td><td rowspan="1" colspan="1">20&#x000b7;1</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">14&#x000b7;0</td><td rowspan="1" colspan="1">4&#x000b7;1</td><td rowspan="1" colspan="1">21&#x000b7;3</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">IL-4-producing cells (Th2 cells) (%CD4<sup>+</sup>
cells)</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">18&#x000b7;2</td><td rowspan="1" colspan="1">41&#x000b7;6</td><td rowspan="1" colspan="1">13&#x000b7;5</td><td rowspan="1" colspan="1">44&#x000b7;3</td><td rowspan="1" colspan="1">&#x02212;4&#x000b7;1</td><td rowspan="1" colspan="1">39&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;870</td><td rowspan="1" colspan="1">0&#x000b7;010</td><td rowspan="1" colspan="1">0&#x000b7;879</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HK L-137</td><td rowspan="1" colspan="1">20&#x000b7;1</td><td rowspan="1" colspan="1">45&#x000b7;0</td><td rowspan="1" colspan="1">14&#x000b7;7</td><td rowspan="1" colspan="1">40&#x000b7;9</td><td rowspan="1" colspan="1">&#x02212;10&#x000b7;9</td><td rowspan="1" colspan="1">21&#x000b7;5</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Th1:Th2 ratio</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">6&#x000b7;6</td><td rowspan="1" colspan="1">48&#x000b7;0</td><td rowspan="1" colspan="1">4&#x000b7;2</td><td rowspan="1" colspan="1">49&#x000b7;1</td><td rowspan="1" colspan="1">35&#x000b7;3</td><td rowspan="1" colspan="1">70&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;449</td><td rowspan="1" colspan="1">0&#x000b7;048</td><td rowspan="1" colspan="1">0&#x000b7;938</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HK L-137</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">51&#x000b7;6</td><td rowspan="1" colspan="1">&#x02013;0&#x000b7;4</td><td rowspan="1" colspan="1">39&#x000b7;6</td><td rowspan="1" colspan="1">22&#x000b7;9</td><td rowspan="1" colspan="1">38&#x000b7;1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Serum IFN-&#x003b2;</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">0&#x000b7;2</td><td rowspan="1" colspan="1">6&#x000b7;8</td><td rowspan="1" colspan="1">&#x02212;0&#x000b7;5</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">4&#x000b7;5</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HK L-137</td><td rowspan="1" colspan="1">&#x02212;5&#x000b7;4</td><td rowspan="1" colspan="1">14&#x000b7;6</td><td rowspan="1" colspan="1">&#x02212;6&#x000b7;7</td><td rowspan="1" colspan="1">31&#x000b7;3</td><td rowspan="1" colspan="1">&#x02212;6&#x000b7;1</td><td rowspan="1" colspan="1">29&#x000b7;5</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn><p>cpm, Counts per min; Con A, concanavalin A; IFN, interferon; Th1, type 1 T
helper; Th2, type 2 T helper.</p></fn><fn><p>* Control group: <italic>n</italic> 15; HK-LP group: <italic>n</italic> 20.</p></fn><fn><p>&#x02020; Significant differences between the two groups at the time points were
evaluated by two-way ANOVA. Serum IFN-&#x003b2; concentrations were compared between the
two groups at each time point by the Mann&#x02013;Whitney <italic>U</italic> test.</p></fn><fn><p>&#x02021; Interaction between intervention and time point.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2-4"><title>Safety assessment</title><p>A total of 151 adverse events related to subjective or objective symptoms were recorded
during the study. Of the seventy-three adverse events in the control group, forty-seven
were symptoms of a common cold, fourteen were digestive symptoms, eight were pain, two
were fatigue, one was furuncle, and one was foot corn. Of the fifty-eight adverse events
in the HK L-137 group, thirty-five were symptoms of a common cold, eight were fatigue,
seven were digestive symptoms, six were pain, one was furuncle, and one was chalazion. All
adverse events were mild, and were judged to be unrelated to the dietary intervention.
Among the safety assessments performed, albumin and diastolic blood pressure were
significantly higher and lactate dehydrogenase was significantly lower in the HK L-137
group than in the control group, but the changes were within the ranges of the
corresponding reference values.</p></sec></sec><sec sec-type="discussion" id="sec3"><title>Discussion</title><p>In the present study, the healthy subjects with high levels of psychological stress who
took HK L-137 daily had a significantly lower incidence of URTI throughout the study. In
addition, the incidence, duration and severity of URTI, and duration of medication showed
significant negative correlations with duration of HK L-137 intake. Among the immune
functions, the percentage change from baseline in Con A-induced proliferation was
significantly greater in the HK L-137 group than in the control group. These findings
suggest the possibility that daily intake of HK L-137 decreases the incidence of URTI
through augmentation of immune functions in healthy subjects.</p><p>Several lines of evidence have shown that dietary consumption of live or heat-killed lactic
acid bacteria can alleviate the symptoms of URTI in human subjects. These studies were
conducted in children<sup>(</sup><xref rid="ref28" ref-type="bibr">
<sup>28</sup>
</xref><sup>)</sup>, elderly individuals<sup>(</sup><xref rid="ref29" ref-type="bibr">
<sup>29</sup>
</xref><sup>&#x02013;</sup><xref rid="ref33" ref-type="bibr">
<sup>33</sup>
</xref><sup>)</sup> and athletes<sup>(</sup><xref rid="ref22" ref-type="bibr">
<sup>22</sup>
</xref><sup>,</sup><xref rid="ref23" ref-type="bibr">
<sup>23</sup>
</xref><sup>)</sup> whose immune functions were not fully developed, decreased with age and
decreased with intense exercise, respectively. In the present study, we recruited subjects
under high levels of psychological stress, who have also been reported to have weak immune
functions and to catch a cold easily<sup>(</sup><xref rid="ref14" ref-type="bibr">
<sup>14</sup>
</xref><sup>&#x02013;</sup><xref rid="ref16" ref-type="bibr">
<sup>16</sup>
</xref><sup>)</sup>. URTI is generally evaluated after diagnosis by a doctor or a
self-rating questionnaire in clinical studies. However, there remain problems associated
with diagnosing the symptoms of URTI in all subjects every day by the same doctor or
validating the self-rating questionnaire for URTI used in each study. The WURSS-21 has been
widely validated and confirmed to perform well as an illness-specific quality-of-life
evaluative outcome instrument<sup>(</sup><xref rid="ref20" ref-type="bibr">
<sup>20</sup>
</xref><sup>)</sup>, and we therefore used it to assess the symptoms of URTI in the present
study.</p><p>We previously reported that healthy subjects with daily intake of HK L-137 showed sustained
increases in Con A-induced proliferation of PBMC, Th1:Th2 ratio of CD4<sup>+</sup> T
cells<sup>(</sup><xref rid="ref9" ref-type="bibr">
<sup>9</sup>
</xref><sup>)</sup> and serum IFN-&#x003b2; concentration<sup>(</sup><xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref><sup>)</sup> from 4 weeks, and that the health-related quality of life also improved
from 8 weeks after the start of dietary intervention<sup>(</sup><xref rid="ref9" ref-type="bibr">
<sup>9</sup>
</xref><sup>)</sup>. In the present study, the incidence of URTI decreased over time in the
control group as well as in the HK L-137 group. It is possible that the epidemic period of
seasonal common cold corresponded to the early part of the dietary intervention, December
2011 to January 2012, so the incidence of URTI decreased in all subjects. However, the
incidence of URTI during the study was significantly lower in the HK L-137 group than in the
control group. The other endpoints such as duration, severity, and duration of medication
showed no differences between the two groups. These results may be influenced by differences
in the timing or frequency of usage of anti-inflammatory drugs between the two groups.
Nevertheless, all endpoints showed significant negative correlations with duration of HK
L-137 intake, suggesting that continued intake of HK L-137 appears to be effective for not
only the incidence but also the symptoms of URTI.</p><p>Immune functions were evaluated in a total of thirty-five subjects who did not contract
URTI during the study and whose immune functions were unlikely to be affected by URTI. Among
the immune functions, the percentage change in Con A-induced proliferation was significantly
higher in the HK L-137 group than in the control group during the study, consistent with our
previous findings. However, the percentage changes in the Th1:Th2 ratios and the amounts of
change in the serum IFN-&#x003b2; concentrations showed no differences between the two groups. It is
well established that psychological stress causes dysregulation of the immune response via
effects on the hypothalamic&#x02013;pituitary&#x02013;adrenal axis and the sympathetic nervous
system<sup>(</sup><xref rid="ref13" ref-type="bibr">
<sup>13</sup>
</xref><sup>)</sup>. The earliest effect has been identified on the central nervous
system-mediated immunoregulatory function involved in the brain's ability to suppress the
transcription of both pro-inflammatory genes (such as <italic>IL1B</italic>,
<italic>IL6</italic> and <italic>TNF</italic>) and antiviral genes (such as
<italic>IFNA</italic> and <italic>IFNB</italic>) by stimulating glucocorticoid release from
the hypothalamic&#x02013;pituitary&#x02013;adrenal axis<sup>(</sup><xref rid="ref34" ref-type="bibr">
<sup>34</sup>
</xref><sup>&#x02013;</sup><xref rid="ref36" ref-type="bibr">
<sup>36</sup>
</xref><sup>)</sup>. Conversely, in the sympathetic nervous system, noradrenaline has been
shown to modulate leucocyte gene expression via stimulation of &#x003b2;-adrenergic receptors, which
are associated with the signalling cascade involving G&#x003b1;<sub>S</sub>, adenylyl cyclase,
cyclic AMP and proteinase A<sup>(</sup><xref rid="ref37" ref-type="bibr">
<sup>37</sup>
</xref><sup>)</sup>. &#x003b2;-Adrenergic signalling has been indicated to modulate adaptive immune
responses by stimulating the transcription of Th2-type cytokine genes (such as
<italic>IL4</italic> and <italic>IL5</italic>) and suppressing the expression of Th1-type
cytokine genes (such as <italic>IFNG</italic> and <italic>IL12B</italic>)<sup>(</sup><xref rid="ref38" ref-type="bibr">
<sup>38</sup>
</xref><sup>&#x02013;</sup><xref rid="ref40" ref-type="bibr">
<sup>40</sup>
</xref><sup>)</sup>. Recent studies have discovered a similar sympathetic nervous
system-mediated suppression of innate immune programmes, involving the suppression of type I
IFN-mediated antiviral responses<sup>(</sup><xref rid="ref41" ref-type="bibr">
<sup>41</sup>
</xref><sup>)</sup> and up-regulated transcription of pro-inflammatory cytokine
genes<sup>(</sup><xref rid="ref42" ref-type="bibr">
<sup>42</sup>
</xref><sup>&#x02013;</sup><xref rid="ref44" ref-type="bibr">
<sup>44</sup>
</xref><sup>)</sup>. Therefore, it is possible that the induction of antiviral (such as
IFN-&#x003b1; and IFN-&#x003b2;) or Th1-type (such as IFN-&#x003b3; and IL-12) cytokines is strongly suppressed in
subjects under high levels of psychological stress, resulting in reduced responses to HK
L-137 intake for inducing IFN-&#x003b2; and IFN-&#x003b3; in the subjects in the present study. Crucial
roles for not only CD8<sup>+</sup> T cells but also CD4<sup>+</sup> T cells in viral
infection have been reported<sup>(</sup><xref rid="ref45" ref-type="bibr">
<sup>45</sup>
</xref><sup>,</sup><xref rid="ref46" ref-type="bibr">
<sup>46</sup>
</xref><sup>)</sup>. Con A-induced T cell proliferation decreases greatly after endurance
race events<sup>(</sup><xref rid="ref47" ref-type="bibr">
<sup>47</sup>
</xref><sup>)</sup>, and endurance athletes are at increased risk for URTI after
marathon-type race events for up to 2 weeks<sup>(</sup><xref rid="ref48" ref-type="bibr">
<sup>48</sup>
</xref><sup>)</sup>. Other studies have indicated that phytohaemagglutinin-induced T cell
proliferation is a good tool for determining the risk of further infection in adult
transplant recipients<sup>(</sup><xref rid="ref49" ref-type="bibr">
<sup>49</sup>
</xref><sup>&#x02013;</sup><xref rid="ref51" ref-type="bibr">
<sup>51</sup>
</xref><sup>)</sup>. The proliferative response of T cells in the HK L-137 group was
enhanced in the present study, which can contribute to reductions in the incidence and
severity of URTI.</p><p>In the measurements of unstimulated proliferation, percentage of IL-4-producing cells, or
Th1:Th2 ratio, a highly significant time point effect was observed (<xref ref-type="table" rid="tab03">Table 3</xref>). Because the methods for measurement of these biomarkers are
based on a highly complicated process including cell culture, measurement noise must be
considered. Intra-assay variation is thought to be lower in measurements at the same time
point than in those at different time points. In addition, measurement reliability can be
enhanced by measuring a control specimen. Therefore, we consider that comparison between
groups at the same time point is reliable but that comparison over time in these cases is
not.</p><p>In conclusion, we have demonstrated that daily intake of HK L-137 decreases the incidence
of URTI in healthy subjects in parallel with augmentation of immunity. The present results
suggest that intake of HK L-137 may be useful for the prevention and treatment of URTI in
healthy individuals.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data"><label>Supplementary Material</label><caption><p>Supplementary information supplied by authors.</p></caption><media xlink:href="S2048679013000359sup001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>There was no funding source in the present study.</p><p>Y. H., Y. Yamamoto and S. M. designed the study. Y. H. conducted the study. Y. H. and S. M.
analysed data; Y. Yoshikai participated in the interpretation of the trial results. Y. H.
wrote the manuscript. S. M. had primary responsibility for the final content of the
manuscript. All authors read and approved the final manuscript.</p><p>All authors have no conflicts of interest.</p></ack><notes id="nts2" notes-type="supplementary-material"><title>Supplementary material</title><p>To view supplementary material for this article, please visit <uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1017/jns.2013.35">http://dx.doi.org/10.1017/jns.2013.35</uri></p></notes><ref-list id="reflist1"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Nomoto</surname><given-names>K</given-names></name> (<year>2008</year>) <article-title>Prevention of postoperative microbial infection
by synbiotics</article-title>. <source>Indian J Exp Biol</source><volume>46</volume>, <fpage>557</fpage>&#x02013;<lpage>561</lpage><pub-id pub-id-type="pmid">18814482</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Isolauri</surname><given-names>E</given-names></name>, <name><surname>Kirjavainen</surname><given-names>PV</given-names></name> &#x00026; <name><surname>Salminen</surname><given-names>S</given-names></name> (<year>2002</year>) <article-title>Probiotics: a role in the treatment of
intestinal infection and inflammation?</article-title><source>Gut</source><volume>50</volume>, <issue>Suppl. 3</issue>,
<fpage>III54</fpage>&#x02013;<lpage>III59</lpage><pub-id pub-id-type="pmid">11953334</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Yasui</surname><given-names>N</given-names></name>, <name><surname>Watanabe</surname><given-names>M</given-names></name>, <name><surname>Iwao</surname><given-names>Y</given-names></name>, <etal/> (<year>1999</year>) <article-title>Laparoscopically assisted bowel
resection for primary mucosa-associated lymphoid tissue lymphoma of the
cecum</article-title>. <source>Surg Laparosc Endosc Percutan Tech</source><volume>9</volume>, <fpage>156</fpage>&#x02013;<lpage>159</lpage><pub-id pub-id-type="pmid">11757546</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Clancy</surname><given-names>R</given-names></name> (<year>2003</year>) <article-title>Immunobiotics and the probiotic
evolution</article-title>. <source>FEMS Immunol Med Microbiol</source><volume>38</volume>, <fpage>9</fpage>&#x02013;<lpage>12</lpage><pub-id pub-id-type="pmid">12900049</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Murosaki</surname><given-names>S</given-names></name>, <name><surname>Yamamoto</surname><given-names>Y</given-names></name>, <name><surname>Ito</surname><given-names>K</given-names></name>, <etal/> (<year>1998</year>) <article-title>Heat-killed <italic>Lactobacillus
plantarum</italic> L-137 suppresses naturally fed antigen-specific IgE production by
stimulation of IL-12 production in mice</article-title>. <source>J Allergy Clin Immunol</source><volume>102</volume>, <fpage>57</fpage>&#x02013;<lpage>64</lpage><pub-id pub-id-type="pmid">9679848</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Murosaki</surname><given-names>S</given-names></name>, <name><surname>Muroyama</surname><given-names>K</given-names></name>, <name><surname>Yamamoto</surname><given-names>Y</given-names></name>, <etal/> (<year>2000</year>) <article-title>Antitumor effect of heat-killed
<italic>Lactobacillus plantarum</italic> L-137 through restoration of impaired
interleukin-12 production in tumor-bearing mice</article-title>. <source>Cancer Immunol
Immunother</source><volume>49</volume>, <fpage>157</fpage>&#x02013;<lpage>164</lpage><pub-id pub-id-type="pmid">10881695</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Hirose</surname><given-names>Y</given-names></name>, <name><surname>Murosaki</surname><given-names>S</given-names></name>, <name><surname>Fujiki</surname><given-names>T</given-names></name>, <etal/> (<year>2010</year>) <article-title>Lipoteichoic acids on
<italic>Lactobacillus plantarum</italic> cell surfaces correlate with induction of
interleukin-12p40 production</article-title>. <source>Microbiol Immunol</source><volume>54</volume>, <fpage>143</fpage>&#x02013;<lpage>151</lpage><pub-id pub-id-type="pmid">20236424</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Fujiki</surname><given-names>T</given-names></name>, <name><surname>Hirose</surname><given-names>Y</given-names></name>, <name><surname>Yamamoto</surname><given-names>Y</given-names></name>, <etal/> (<year>2012</year>) <article-title>Enhanced immunomodulatory activity and
stability in simulated digestive juices of <italic>Lactobacillus plantarum</italic>
L-137 by heat treatment</article-title>. <source>Biosci Biotechnol Biochem</source><volume>76</volume>, <fpage>918</fpage>&#x02013;<lpage>922</lpage><pub-id pub-id-type="pmid">22738959</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Hirose</surname><given-names>Y</given-names></name>, <name><surname>Murosaki</surname><given-names>S</given-names></name>, <name><surname>Yamamoto</surname><given-names>Y</given-names></name>, <etal/> (<year>2006</year>) <article-title>Daily intake of heat-killed
<italic>Lactobacillus plantarum</italic> L-137 augments acquired immunity in healthy
adults</article-title>. <source>J Nutr</source><volume>136</volume>, <fpage>3069</fpage>&#x02013;<lpage>3073</lpage><pub-id pub-id-type="pmid">17116721</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Maeda</surname><given-names>N</given-names></name>, <name><surname>Nakamura</surname><given-names>R</given-names></name>, <name><surname>Hirose</surname><given-names>Y</given-names></name>, <etal/> (<year>2009</year>) <article-title>Oral administration of heat-killed
<italic>Lactobacillus plantarum</italic> L-137 enhances protection against influenza
virus infection by stimulation of type I interferon production in mice</article-title>.
<source>Int Immunopharmacol</source><volume>9</volume>, <fpage>1122</fpage>&#x02013;<lpage>1125</lpage><pub-id pub-id-type="pmid">19410659</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Arimori</surname><given-names>Y</given-names></name>, <name><surname>Nakamura</surname><given-names>R</given-names></name>, <name><surname>Hirose</surname><given-names>Y</given-names></name>, <etal/> (<year>2012</year>) <article-title>Daily intake of heat-killed
<italic>Lactobacillus plantarum</italic> L-137 enhances type I interferon production
in healthy humans and pigs</article-title>. <source>Immunopharmacol Immunotoxicol</source><volume>34</volume>, <fpage>937</fpage>&#x02013;<lpage>943</lpage><pub-id pub-id-type="pmid">22468623</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Kaminogawa</surname><given-names>S</given-names></name> &#x00026; <name><surname>Nanno</surname><given-names>M</given-names></name> (<year>2004</year>) <article-title>Modulation of immune functions by
foods</article-title>. <source>Evid Based Complement Alternat Med</source><volume>1</volume>, <fpage>241</fpage>&#x02013;<lpage>250</lpage><pub-id pub-id-type="pmid">15841257</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Irwin</surname><given-names>MR</given-names></name> &#x00026; <name><surname>Cole</surname><given-names>SW</given-names></name> (<year>2011</year>) <article-title>Reciprocal regulation of the neural and innate
immune systems</article-title>. <source>Nat Rev Immunol</source><volume>11</volume>, <fpage>625</fpage>&#x02013;<lpage>632</lpage><pub-id pub-id-type="pmid">21818124</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>S</given-names></name>, <name><surname>Tyrrell</surname><given-names>DA</given-names></name> &#x00026; <name><surname>Smith</surname><given-names>AP</given-names></name> (<year>1991</year>) <article-title>Psychological stress and susceptibility to the
common cold</article-title>. <source>N Engl J Med</source><volume>325</volume>, <fpage>606</fpage>&#x02013;<lpage>612</lpage><pub-id pub-id-type="pmid">1713648</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>S</given-names></name>, <name><surname>Tyrrell</surname><given-names>DA</given-names></name> &#x00026; <name><surname>Smith</surname><given-names>AP</given-names></name> (<year>1993</year>) <article-title>Negative life events, perceived stress,
negative affect, and susceptibility to the common cold</article-title>. <source>J Pers
Soc Psychol</source><volume>64</volume>, <fpage>131</fpage>&#x02013;<lpage>140</lpage><pub-id pub-id-type="pmid">8421249</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>S</given-names></name>, <name><surname>Frank</surname><given-names>E</given-names></name>, <name><surname>Doyle</surname><given-names>WJ</given-names></name>, <etal/> (<year>1998</year>) <article-title>Types of stressors that increase
susceptibility to the common cold in healthy adults</article-title>. <source>Health
Psychol</source><volume>17</volume>, <fpage>214</fpage>&#x02013;<lpage>223</lpage><pub-id pub-id-type="pmid">9619470</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Kerr</surname><given-names>JR</given-names></name> &#x00026; <name><surname>Mattey</surname><given-names>DL</given-names></name> (<year>2008</year>) <article-title>Preexisting psychological stress predicts acute
and chronic fatigue and arthritis following symptomatic parvovirus B19
infection</article-title>. <source>Clin Infect Dis</source><volume>46</volume>, <fpage>e83</fpage>&#x02013;<lpage>e87</lpage><pub-id pub-id-type="pmid">18419428</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Douglas</surname><given-names>RM</given-names></name> (<year>1999</year>) <article-title>Respiratory tract infections as a public health
challenge</article-title>. <source>Clin Infect Dis</source><volume>28</volume>, <fpage>192</fpage>&#x02013;<lpage>194</lpage><pub-id pub-id-type="pmid">10064224</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>Barrett</surname><given-names>B</given-names></name>, <name><surname>Locken</surname><given-names>K</given-names></name>, <name><surname>Maberry</surname><given-names>R</given-names></name>, <etal/> (<year>2002</year>) <article-title>The Wisconsin Upper Respiratory
Symptom Survey: development of an instrument to measure the common cold</article-title>.
<source>J Fam Pract</source><volume>51</volume>, <fpage>265</fpage>&#x02013;<lpage>273</lpage><pub-id pub-id-type="pmid">11978238</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Barrett</surname><given-names>B</given-names></name>, <name><surname>Brown</surname><given-names>RL</given-names></name>, <name><surname>Mundt</surname><given-names>MP</given-names></name>, <etal/> (<year>2009</year>) <article-title>Validation of a short form Wisconsin
Upper Respiratory Symptom Survey (WURSS-21)</article-title>. <source>Health Qual Life
Outcomes</source><volume>7</volume>, 76.</mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="book"><name><surname>Shimomitsu</surname><given-names>T</given-names></name> (<year>2000</year>) <chapter-title>The final development of the Brief Job Stress
Questionnaire mainly used for assessment of the individuals</chapter-title> In
<source>Ministry of Labour Sponsored Grant for the Prevention of Work-Related Illness:
The 1999 Report</source>, pp. <fpage>126</fpage>&#x02013;<lpage>164</lpage> [<string-name>
<given-names>M</given-names>
<surname>Kato</surname>
</string-name>, editor]. <publisher-loc>Tokyo</publisher-loc>: <publisher-name>Tokyo
Medical College</publisher-name></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Gleeson</surname><given-names>M</given-names></name>, <name><surname>Bishop</surname><given-names>NC</given-names></name>, <name><surname>Oliveira</surname><given-names>M</given-names></name>, <etal/> (<year>2011</year>) <article-title>Daily probiotic's
(<italic>Lactobacillus casei</italic> Shirota) reduction of infection incidence in
athletes</article-title>. <source>Int J Sport Nutr Exerc Metab</source><volume>21</volume>, <fpage>55</fpage>&#x02013;<lpage>64</lpage><pub-id pub-id-type="pmid">21411836</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>West</surname><given-names>NP</given-names></name>, <name><surname>Pyne</surname><given-names>DB</given-names></name>, <name><surname>Cripps</surname><given-names>AW</given-names></name>, <etal/> (<year>2011</year>) <article-title><italic>Lactobacillus
fermentum</italic> (PCC<sup>&#x000ae;</sup>) supplementation and gastrointestinal and
respiratory-tract illness symptoms: a randomised control trial in
athletes</article-title>. <source>Nutr J</source><volume>10</volume>, 30.</mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Neville</surname><given-names>V</given-names></name>, <name><surname>Gleeson</surname><given-names>M</given-names></name> &#x00026; <name><surname>Folland</surname><given-names>JP</given-names></name> (<year>2008</year>) <article-title>Salivary IgA as a risk factor for upper
respiratory infections in elite professional athletes</article-title>. <source>Med Sci
Sports Exerc</source><volume>40</volume>, <fpage>1228</fpage>&#x02013;<lpage>1236</lpage><pub-id pub-id-type="pmid">18580401</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Openshaw</surname><given-names>P</given-names></name>, <name><surname>Murphy</surname><given-names>EE</given-names></name>, <name><surname>Hosken</surname><given-names>NA</given-names></name>, <etal/> (<year>1995</year>) <article-title>Heterogeneity of intracellular
cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2
populations</article-title>. <source>J Exp Med</source><volume>182</volume>, <fpage>1357</fpage>&#x02013;<lpage>1367</lpage><pub-id pub-id-type="pmid">7595206</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Friedman</surname><given-names>M</given-names></name> (<year>1937</year>) <article-title>The use of ranks to avoid the assumption of
normality implicit in the analysis of variance</article-title>. <source>J Am Stat Assoc</source><volume>32</volume>, <fpage>675</fpage>&#x02013;<lpage>701</lpage></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Conover</surname><given-names>WJ</given-names></name> &#x00026; <name><surname>Iman</surname><given-names>RL</given-names></name> (<year>1981</year>) <article-title>Rank transformation as a bridge between
parametric and non-parametric statistics</article-title>. <source>Am Statistician</source><volume>35</volume>, <fpage>124</fpage>&#x02013;<lpage>129</lpage></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Hatakka</surname><given-names>K</given-names></name>, <name><surname>Savilahti</surname><given-names>E</given-names></name>, <name><surname>Ponka</surname><given-names>A</given-names></name>, <etal/> (<year>2001</year>) <article-title>Effect of long term consumption of
probiotic milk on infections in children attending day care centres: double blind,
randomised trial</article-title>. <source>BMJ</source><volume>322</volume>, 1327.</mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Fukushima</surname><given-names>Y</given-names></name>, <name><surname>Miyaguchi</surname><given-names>S</given-names></name>, <name><surname>Yamano</surname><given-names>T</given-names></name>, <etal/> (<year>2007</year>) <article-title>Improvement of nutritional status and
incidence of infection in hospitalised, enterally fed elderly by feeding of fermented
milk containing probiotic <italic>Lactobacillus johnsonii</italic> La1
(NCC533)</article-title>. <source>Br J Nutr</source><volume>98</volume>, <fpage>969</fpage>&#x02013;<lpage>977</lpage><pub-id pub-id-type="pmid">17617944</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Guillemard</surname><given-names>E</given-names></name>, <name><surname>Tondu</surname><given-names>F</given-names></name>, <name><surname>Lacoin</surname><given-names>F</given-names></name><etal/> (<year>2010</year>) <article-title>Consumption of a fermented dairy product
containing the probiotic <italic>Lactobacillus casei</italic> DN-114001 reduces the
duration of respiratory infections in the elderly in a randomised controlled
trial</article-title>. <source>Br J Nutr</source><volume>103</volume>, <fpage>58</fpage>&#x02013;<lpage>68</lpage><pub-id pub-id-type="pmid">19747410</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><name><surname>Makino</surname><given-names>S</given-names></name>, <name><surname>Ikegami</surname><given-names>S</given-names></name>, <name><surname>Kume</surname><given-names>A</given-names></name>, <etal/> (<year>2010</year>) <article-title>Reducing the risk of infection in the
elderly by dietary intake of yoghurt fermented with <italic>Lactobacillus
delbrueckii</italic> ssp. bulgaricus OLL1073R-1</article-title>. <source>Br J Nutr</source><volume>104</volume>, <fpage>998</fpage>&#x02013;<lpage>1006</lpage><pub-id pub-id-type="pmid">20487575</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>Van Puyenbroeck</surname><given-names>K</given-names></name>, <name><surname>Hens</surname><given-names>N</given-names></name>, <name><surname>Coenen</surname><given-names>S</given-names></name>, <etal/> (<year>2012</year>) <article-title>Efficacy of daily intake of
<italic>Lactobacillus casei</italic> Shirota on respiratory symptoms and influenza
vaccination immune response: a randomized, double-blind, placebo-controlled trial in
healthy elderly nursing home residents</article-title>. <source>Am J Clin Nutr</source><volume>95</volume>, <fpage>1165</fpage>&#x02013;<lpage>1171</lpage><pub-id pub-id-type="pmid">22440853</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><name><surname>Shinkai</surname><given-names>S</given-names></name>, <name><surname>Toba</surname><given-names>M</given-names></name>, <name><surname>Saito</surname><given-names>T</given-names></name>, <etal/> (<year>2013</year>) <article-title>Immunoprotective effects of oral
intake of heat-killed <italic>Lactobacillus pentosus</italic> strain b240 in elderly
adults: a randomised, double-blind, placebo-controlled trial</article-title>. <source>Br
J Nutr</source><volume>109</volume>, <fpage>1856</fpage>&#x02013;<lpage>1865</lpage><pub-id pub-id-type="pmid">22947249</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>Besedovsky</surname><given-names>H</given-names></name>, <name><surname>del Rey</surname><given-names>A</given-names></name>, <name><surname>Sorkin</surname><given-names>E</given-names></name><etal/> (<year>1986</year>) <article-title>Immunoregulatory feedback between interleukin-1
and glucocorticoid hormones</article-title>. <source>Science</source><volume>233</volume>, <fpage>652</fpage>&#x02013;<lpage>654</lpage><pub-id pub-id-type="pmid">3014662</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Sapolsky</surname><given-names>R</given-names></name>, <name><surname>Rivier</surname><given-names>C</given-names></name>, <name><surname>Yamamoto</surname><given-names>G</given-names></name>, <etal/> (<year>1987</year>) <article-title>Interleukin-1 stimulates the secretion
of hypothalamic corticotropin-releasing factor</article-title>. <source>Science</source><volume>238</volume>, <fpage>522</fpage>&#x02013;<lpage>524</lpage><pub-id pub-id-type="pmid">2821621</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><name><surname>Berkenbosch</surname><given-names>F</given-names></name>, <name><surname>van Oers</surname><given-names>J</given-names></name>, <name><surname>del Rey</surname><given-names>A</given-names></name>, <etal/> (<year>1987</year>) <article-title>Corticotropin-releasing
factor-producing neurons in the rat activated by interleukin-1</article-title>.
<source>Science</source><volume>238</volume>, <fpage>524</fpage>&#x02013;<lpage>526</lpage><pub-id pub-id-type="pmid">2443979</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><name><surname>Nance</surname><given-names>DM</given-names></name> &#x00026; <name><surname>Sanders</surname><given-names>VM</given-names></name> (<year>2007</year>) <article-title>Autonomic innervation and regulation of the
immune system (1987&#x02013;2007)</article-title>. <source>Brain Behav Immun</source><volume>21</volume>, <fpage>736</fpage>&#x02013;<lpage>745</lpage><pub-id pub-id-type="pmid">17467231</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>HJ</given-names></name>, <name><surname>Takemoto</surname><given-names>N</given-names></name>, <name><surname>Kurata</surname><given-names>H</given-names></name>, <etal/> (<year>2000</year>) <article-title>GATA-3 induces T helper cell type 2
(Th2) cytokine expression and chromatin remodeling in committed Th1
cells</article-title>. <source>J Exp Med</source><volume>192</volume>, <fpage>105</fpage>&#x02013;<lpage>115</lpage><pub-id pub-id-type="pmid">10880531</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><name><surname>Panina-Bordignon</surname><given-names>P</given-names></name>, <name><surname>Mazzeo</surname><given-names>D</given-names></name>, <name><surname>Lucia</surname><given-names>PD</given-names></name>, <etal/> (<year>1997</year>) <article-title>Beta2-agonists prevent Th1 development
by selective inhibition of interleukin 12</article-title>. <source>J Clin Invest</source><volume>100</volume>, <fpage>1513</fpage>&#x02013;<lpage>1519</lpage><pub-id pub-id-type="pmid">9294119</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><name><surname>Cole</surname><given-names>SW</given-names></name>, <name><surname>Korin</surname><given-names>YD</given-names></name>, <name><surname>Fahey</surname><given-names>JL</given-names></name><etal/> (<year>1998</year>) <article-title>Norepinephrine accelerates HIV replication via
protein kinase A-dependent effects on cytokine production</article-title>. <source>J
Immunol</source><volume>161</volume>, <fpage>610</fpage>&#x02013;<lpage>616</lpage><pub-id pub-id-type="pmid">9670934</pub-id></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><name><surname>Collado-Hidalgo</surname><given-names>A</given-names></name>, <name><surname>Sung</surname><given-names>C</given-names></name> &#x00026; <name><surname>Cole</surname><given-names>S</given-names></name> (<year>2006</year>) <article-title>Adrenergic inhibition of innate anti-viral
response: PKA blockade of type I interferon gene transcription mediates catecholamine
support for HIV-1 replication</article-title>. <source>Brain Behav Immun</source><volume>20</volume>, <fpage>552</fpage>&#x02013;<lpage>563</lpage><pub-id pub-id-type="pmid">16504464</pub-id></mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><name><surname>Cole</surname><given-names>SW</given-names></name>, <name><surname>Arevalo</surname><given-names>JM</given-names></name>, <name><surname>Takahashi</surname><given-names>R</given-names></name>, <etal/> (<year>2010</year>) <article-title>Computational identification of
gene&#x02013;social environment interaction at the human IL6 locus</article-title>. <source>Proc
Natl Acad Sci U S A</source><volume>107</volume>, <fpage>5681</fpage>&#x02013;<lpage>5686</lpage><pub-id pub-id-type="pmid">20176930</pub-id></mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><name><surname>Grebe</surname><given-names>KM</given-names></name>, <name><surname>Takeda</surname><given-names>K</given-names></name>, <name><surname>Hickman</surname><given-names>HD</given-names></name>, <etal/> (<year>2009</year>) <article-title>Cutting edge: sympathetic nervous
system increases proinflammatory cytokines and exacerbates influenza A virus
pathogenesis</article-title>. <source>J Immunol</source><volume>184</volume>, <fpage>540</fpage>&#x02013;<lpage>544</lpage><pub-id pub-id-type="pmid">20018617</pub-id></mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><name><surname>Cole</surname><given-names>SW</given-names></name>, <name><surname>Hawkley</surname><given-names>LC</given-names></name>, <name><surname>Arevalo</surname><given-names>JM</given-names></name>, <etal/> (<year>2007</year>) <article-title>Social regulation of gene expression
in human leukocytes</article-title>. <source>Genome Biol</source><volume>8</volume>, R189.</mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><name><surname>Matloubian</surname><given-names>M</given-names></name>, <name><surname>Concepcion</surname><given-names>RJ</given-names></name> &#x00026; <name><surname>Ahmed</surname><given-names>R</given-names></name> (<year>1994</year>) <article-title>CD4<sup>+</sup> T cells are required to sustain
CD8<sup>+</sup> cytotoxic T-cell responses during chronic viral
infection</article-title>. <source>J Virol</source><volume>68</volume>, <fpage>8056</fpage>&#x02013;<lpage>8063</lpage><pub-id pub-id-type="pmid">7966595</pub-id></mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><name><surname>Shedlock</surname><given-names>DJ</given-names></name> &#x00026; <name><surname>Shen</surname><given-names>H</given-names></name> (<year>2003</year>) <article-title>Requirement for CD4 T cell help in generating
functional CD8 T cell memory</article-title>. <source>Science</source><volume>300</volume>, <fpage>337</fpage>&#x02013;<lpage>339</lpage><pub-id pub-id-type="pmid">12690201</pub-id></mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal"><name><surname>Nieman</surname><given-names>DC</given-names></name> (<year>1997</year>) <article-title>Immune response to heavy
exertion</article-title>. <source>J Appl Physiol</source><volume>82</volume>, <fpage>1385</fpage>&#x02013;<lpage>1394</lpage><pub-id pub-id-type="pmid">9134882</pub-id></mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal"><name><surname>Nieman</surname><given-names>DC</given-names></name> (<year>1997</year>) <article-title>Risk of upper respiratory tract infection in
athletes: an epidemiologic and immunologic perspective</article-title>. <source>J Athl
Train</source><volume>32</volume>, <fpage>344</fpage>&#x02013;<lpage>349</lpage><pub-id pub-id-type="pmid">16558471</pub-id></mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal"><name><surname>Blazik</surname><given-names>M</given-names></name>, <name><surname>Hutchinson</surname><given-names>P</given-names></name>, <name><surname>Jose</surname><given-names>MD</given-names></name>, <etal/> (<year>2005</year>) <article-title>Leukocyte phenotype and function
predicts infection risk in renal transplant recipients</article-title>. <source>Nephrol
Dial Transplant</source><volume>20</volume>, <fpage>2226</fpage>&#x02013;<lpage>2230</lpage><pub-id pub-id-type="pmid">16030032</pub-id></mixed-citation></ref><ref id="ref50"><label>50.</label><mixed-citation publication-type="journal"><name><surname>Rodrigo</surname><given-names>E</given-names></name>, <name><surname>Lopez-Hoyos</surname><given-names>M</given-names></name>, <name><surname>Corral</surname><given-names>M</given-names></name>, <etal/> (<year>2012</year>) <article-title>ImmuKnow as a diagnostic tool for
predicting infection and acute rejection in adult liver transplant recipients: a
systematic review and meta-analysis</article-title>. <source>Liver Transpl</source><volume>18</volume>, <fpage>1245</fpage>&#x02013;<lpage>1253</lpage><pub-id pub-id-type="pmid">22740321</pub-id></mixed-citation></ref><ref id="ref51"><label>51.</label><mixed-citation publication-type="journal"><name><surname>Moon</surname><given-names>HH</given-names></name>, <name><surname>Kim</surname><given-names>TS</given-names></name>, <name><surname>Roh</surname><given-names>YN</given-names></name>, <etal/> (<year>2012</year>) <article-title>Can immune function assay predict
infection or recovery?</article-title><source>Transplant Proc</source><volume>44</volume>, <fpage>1048</fpage>&#x02013;<lpage>1051</lpage><pub-id pub-id-type="pmid">22564622</pub-id></mixed-citation></ref></ref-list></back></article>